Einzeltreffer — DigiBib

High grade epithelial ovarian carcinoma is an aggressive tumor. Treatment includes platinum therapy, however it recurs in most patients due to therapy resistance. In this project, we study the immunohistochemical (IHC) expression of five potential biomarkers/prognostic markers in high grade epithelial ovarian carcinoma: EGFR, HLA-G, CD70, c-MET, and NY-ESO1. A cohort of 274 patients is used. We compare the IHC expression with age, stage, ascites status, family history of cancer, disease free survival (DFS) and overall survival (OS). EGFR expression is significantly correlated with family history and worse OS. HLA-G is associated with worse OS. To confirm the results of EGFR and HLA-G, a second separated cohort of 248 patients is used. Positive EGFR expression again shows worse OS, while HLA-G expression has worse prognostic trend. CD70 has a worse OS trend. C-MET and NY-ESO1 do not have any clinical correlations. EGFR can potentially serve as target in future clinical immune therapy trials.

Titel:	EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
Autor/in / Beteiligte Person:	Vo, D ; Liu, Y ; Sood, AK ; Rezvani, K ; Jazaeri, AA ; Liu, J
Zeitschrift:	Cancer biomarkers : section A of Disease markers, Jg. 39 (2024), Heft 4, S. 289-298
Veröffentlichung:	Amsterdam ; Washington, DC : IOS Press, c2005-, 2024
Medientyp:	academicJournal
ISSN:	1875-8592 (electronic)
DOI:	10.3233/CBM-230200
Schlagwort:	Humans Female Middle Aged Prognosis Aged Adult Neoplasm Grading Immunohistochemistry Aged, 80 and over Biomarkers, Tumor metabolism Membrane Proteins metabolism Proto-Oncogene Proteins c-met metabolism ErbB Receptors metabolism Carcinoma, Ovarian Epithelial pathology Carcinoma, Ovarian Epithelial metabolism Carcinoma, Ovarian Epithelial mortality Ovarian Neoplasms metabolism Ovarian Neoplasms pathology Ovarian Neoplasms mortality Antigens, Neoplasm metabolism HLA-G Antigens metabolism
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Cancer Biomark] 2024; Vol. 39 (4), pp. 289-298. MeSH Terms: Biomarkers, Tumor* / metabolism ; Membrane Proteins* / metabolism ; Proto-Oncogene Proteins c-met* / metabolism ; ErbB Receptors* / metabolism ; Carcinoma, Ovarian Epithelial* / pathology ; Carcinoma, Ovarian Epithelial* / metabolism ; Carcinoma, Ovarian Epithelial* / mortality ; Ovarian Neoplasms* / metabolism ; Ovarian Neoplasms* / pathology ; Ovarian Neoplasms* / mortality ; Antigens, Neoplasm* / metabolism ; HLA-G Antigens* / metabolism ; Humans ; Female ; Middle Aged ; Prognosis ; Aged ; Adult ; Neoplasm Grading ; Immunohistochemistry ; Aged, 80 and over References: Hum Immunol. 2009 Dec;70(12):1006-9. (PMID: 19660509) ; Mol Cancer. 2018 Feb 19;17(1):45. (PMID: 29455668) ; Biomed Res Int. 2014;2014:934261. (PMID: 24868556) ; Genes Cancer. 2017 May;8(5-6):589-599. (PMID: 28740577) ; Reprod Sci. 2017 Apr;24(4):494-501. (PMID: 27170665) ; Int J Mol Sci. 2019 Sep 22;20(19):. (PMID: 31546690) ; CA Cancer J Clin. 2018 Jul;68(4):284-296. (PMID: 29809280) ; Mol Med. 2015 Nov;21(1):782-791. (PMID: 26322846) ; APMIS. 2009 Mar;117(3):162-75. (PMID: 19245589) ; Int J Womens Health. 2019 Apr 30;11:287-299. (PMID: 31118829) ; Cancer Sci. 2021 Sep;112(9):3655-3668. (PMID: 34117815) ; J Gynecol Oncol. 2016 May;27(3):e25. (PMID: 27029746) ; Int J Mol Sci. 2021 Nov 27;22(23):. (PMID: 34884633) ; Pathobiology. 2016;83(6):327-33. (PMID: 27389010) ; J Immunol Res. 2014;2014:274584. (PMID: 24987709) ; Int J Mol Sci. 2021 Jun 18;22(12):. (PMID: 34207103) ; Onco Targets Ther. 2013 Jun 05;6:615-9. (PMID: 23776334) ; Reprod Sci. 2009 Nov;16(11):1103-11. (PMID: 19692629) ; BMC Cancer. 2011 Jul 14;11:294. (PMID: 21756326) ; Am J Pathol. 2016 Apr;186(4):733-47. (PMID: 27012190) ; Mol Oncol. 2018 Jan;12(1):3-20. (PMID: 29124875) ; Biomark Med. 2013 Oct;7(5):803-19. (PMID: 24044572) ; Br J Cancer. 2008 Jul 22;99(2):341-9. (PMID: 18628764) ; Obstet Gynecol. 2017 Mar;129(3):439-447. (PMID: 28178043) ; Gynecol Oncol. 2017 Jun;145(3):420-425. (PMID: 28392127) ; Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38. (PMID: 29249039) ; Gastric Cancer. 2016 Jan;19(1):183-91. (PMID: 25682441) ; J Transl Med. 2020 Mar 27;18(1):140. (PMID: 32220256) ; Discov Med. 2018 Nov;26(144):219-229. (PMID: 30695681) ; Genes Dis. 2019 Dec 20;8(1):25-37. (PMID: 33569511) Grant Information: P50 CA281701 United States CA NCI NIH HHS Contributed Indexing: Keywords: CD70; EGFR; HLA-G; NY-ESO1; c-MET; survival Substance Nomenclature: 0 (Biomarkers, Tumor) ; 0 (Membrane Proteins) ; EC 2.7.10.1 (Proto-Oncogene Proteins c-met) ; EC 2.7.10.1 (ErbB Receptors) ; 0 (CTAG1B protein, human) ; EC 2.7.10.1 (EGFR protein, human) ; 0 (Antigens, Neoplasm) ; 0 (HLA-G Antigens) ; EC 2.7.10.1 (MET protein, human) Entry Date(s): Date Created: 20240122 Date Completed: 20240510 Latest Revision: 20240516 Update Code: 20240516 PubMed Central ID: PMC11091604

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.